Cytokinetics Inc (CYTK)
45.10
+0.09 (+0.20%)
USD |
NASDAQ |
Feb 06, 10:30
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 4.268B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 40.26% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 26.52 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -38.09 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 65.24% |
News
Headline
Wire
Time (ET)
Globe Newswire
02/01 16:00
Globe Newswire
01/30 07:30
Yahoo
01/25 06:26
MT Newswires
01/17 10:05
Globe Newswire
01/03 16:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 02/24/2023* | 16:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 02/24/2023* | -- | Results | Q4 2022 | -- | -1.19 | -- | |
| 11/03/2022 | 16:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 11/03/2022 | -- | Results | Q3 2022 | -1.28 | -1.18 | -8.92% | |
| 08/04/2022 | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/04/2022 | -- | Results | Q2 2022 | -0.23 | -1.01 | 77.32% | |
| 05/04/2022 | 16:30 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 05/04/2022 | -- | Results | Q1 2022 | -1.02 | -0.94 | -9.05% |
*Estimated Date/Time
Earnings
Profile
Edit
| Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. |
| URL | https://cytokinetics.com |
| Investor Relations URL | https://ir.cytokinetics.com |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Feb. 24, 2023 (est.) |
| Last Earnings Release | Nov. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of February 03, 2023.
Fundamentals
| Revenue (TTM) | 148.23M |
| Total Expenses (TTM) | 367.11M |
| Net Income (TTM) | -282.14M |
| Total Assets (Quarterly) | 1.076B |
| Total Liabilities (Quarterly) | 1.092B |
| Shareholders Equity (Quarterly) | -15.98M |
| Cash from Operations (TTM) | -246.06M |
| Cash from Investing (TTM) | -244.05M |
| Cash from Financing (TTM) | 505.79M |
Ratings
Profile
Edit
| Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. |
| URL | https://cytokinetics.com |
| Investor Relations URL | https://ir.cytokinetics.com |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Feb. 24, 2023 (est.) |
| Last Earnings Release | Nov. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| FIJYX | 54.12M USD | 3.02% |
| FBIOX | 98.72M USD | 1.91% |
| LADSX | 45.97M USD | 1.77% |
| LGLQX | 85.91M USD | 1.58% |
| XBI | 96.38M USD | 1.11% |
| SLYG | 20.94M USD | 0.84% |
| IJT | 44.87M USD | 0.82% |
| SPSM | 23.08M USD | 0.43% |
| VSMSX | 18.34M USD | 0.42% |
| VIOO | 18.34M USD | 0.42% |
| VTSIX | 36.25M USD | 0.42% |
| IJR | 301.71M USD | 0.42% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| CYTK Tweets |